About Takeda Pharmaceutical
Millennium Pharmaceuticals was established in 1993 as a genomics company, applying world-class molecular biology and genomic technologies to the discovery and development of new therapies in a broad spectrum of diseases. Over time we evolved into a fully integrated biopharmaceutical company.
In May 2008, Millennium was acquired by Takeda Pharmaceutical Company Limited in Japan and became known as Millennium: The Takeda Oncology Company (Millennium), a wholly-owned subsidiary of Takeda that served as the organization’s global center of excellence in oncology.
The combination of oncology resources resulted in a robust pipeline that addresses a broad range of cancers. Our focus is to improve the treatment of cancer, which gives us an important oncology mission to deliver extraordinary medicines to patients with cancer worldwide through our science, innovation and passion, toward an ultimate goal and aspiration to cure cancer.
In May 2013, the decision was made to fully integrate Millennium into the global Takeda R&D engine to maximize the resources available from the broader Takeda organization and to realize greater operational efficiencies. The R&D and G&A functions in Boston became known publically as Takeda Pharmaceuticals International Co. The oncology Commercial, Business Development and Patient Advocacy divisions continue to operate as Millennium: The Takeda Oncology Company.
At Takeda and Millennium, we want to exceed expectations in terms of progress against cancer, distinguishing ourselves within the research-based biopharmaceutical community. We’re prepared to deliver on this goal by focusing on novel or best-in-class drug candidates, and cultivating the brightest talent. This puts Takeda on an exciting path toward global oncology leadership.
We help drive and accelerate the progress that continually is being made against cancer; these advances, sometimes big breakthroughs and sometimes incremental, make a real difference in the lives of patients. We won’t be satisfied until cures are found and the threat is removed. People who battle cancer deserve no less.
Our goal also is to provide patients and people close to them with easily understandable information about the diseases our products treat, as well as other relevant information and service resources. We also provide information about our investigational drugs that are approaching or in development, our clinical trials, and what patients, caregivers and healthcare providers need to know about our assistance and access programs for any drug we currently market. We work toward our goals with the same urgency for patients that we would for our families. We strive to earn the respect and admiration of the global oncology community by delivering significant progress against cancer while living our core values.
The people and culture at Takeda and Millennium make all the difference.
Our work is more than a job. We are entrepreneurial about both our work and achieving progress. We focus on what’s important and timely decision-making.
As a site based in New England, we enjoy our local community and contribute in many ways to local business, social and environmental causes. We offer a broad range of opportunities for campus-based employees to participate. We also involve ourselves on a corporate level in matters of social responsibility.
June 12, 1781
Founder: Chobei Takeda
CEO: Christophe Weber
CMO (Medical) and CSO (Scientific): Andrew Plump
CFO: James Kehoe
Tweets by Takeda
1204 articles with Takeda Pharmaceutical
Major players in the biotech industry are moving full steam ahead in their 2021 operations goals despite the ongoing pandemic, with global pharmaceutical giant Takeda being no exception.
BioSpace takes a look at some of the announcements that occurred Monday and will continue to update throughout the week.
Takeda Provides Pipeline Update and Shares Goal to Increase Revenue 50% by FY2030 at the 39th Annual J.P. Morgan Healthcare Conference
− Goal to Reach JPY5 Trillion ($47 Billion) Revenue by FY2030 1 , Representing 50% Growth from FY2019 − Wave 1 Pipeline Portfolio Includes 12 New Molecular Entities Targeted for Launch by FY2024 Representing Best-in-Class/First-in-Class Therapies with Significant Market Potential − Rapid Deleveraging On Track to Achieve Target of 2x Net Debt / adjusted EBITDA within Fiscal Years 2021 to 2023
Takeda Pharmaceutical Company Limited announced the completion of its previously-announced sale of a portfolio of select prescription products to Cheplapharm for a total value of $562 million USD.
Takeda Furthers Innovation-Focused Strategy in China with Sale of Select Non-Core Assets to Hasten for $322 million USD
Takeda continues to execute on global strategy focused on life-transforming treatments for patients living with complex and rare diseases
U.S. Food and Drug Administration Accepts New Drug Application for Review, Grants Priority Review for Takeda’s TAK-721 (budesonide oral suspension) for the Treatment of Eosinophilic Esophagitis
− If approved, TAK-721 will be the first FDA-approved treatment for the chronic inflammatory disease; Takeda plans to use the trade name Eohilia (budesonide oral suspension)
Crescendo Biologics Ltd, the drug developer of novel, targeted T cell enhancing therapeutics, announced that it has expanded its global, multi-target discovery and development collaboration with Takeda Pharmaceutical Company Limited after Crescendo achieved its sixth technical milestone.
Company Aiming for Mid-Single-Digit Revenue CAGR Over Next Decade Amounting to JPY5 Trillion ($47 Billion) by FY2030
Takeda Announces Approval of TAKHZYRO® (lanadelumab) subcutaneous injection in China for the Treatment of Hereditary Angioedema
TAKHZYRO is the first approved modern therapy for the preventive treatment of hereditary angioedema (HAE) in patients 12 years and older in China1
Takeda Presents Real-World Evidence at ASH 2020, Demonstrating Its Long-Standing Commitment to Personalizing Treatments for Rare Bleeding Disorders
- Key learnings from real-world data and retrospective studies from nine abstracts are presented at the 62 nd ASH Annual Meeting & Exposition, taking place virtually this year - Takeda continues to gather and apply real-world evidence in the treatment of hemophilia, von Willebrand disease (VWD) and sickle cell disease (SCD) and advance personalized treatment in its ongoing commitment to people living with bleeding disorders
New Phase 3 Data Show TAK-620 (maribavir), an Investigational Drug for the Treatment of Transplant Recipients with Refractory/Resistant Cytomegalovirus (CMV) Infections, Meets Primary Endpoint
Primary endpoint defined as the proportion of patients who achieved confirmed CMV viremia clearance at the end of Study Week 8
Further sharpens Takeda’s focus on ‘fast tracking’ patient access to highly innovative medicines for complex and rare diseases in Asia Pacific and the Emerging Markets
Celltrion Completes Acquisition of Primary Care (PC) Product Assets for Asia Pacific Markets from Takeda Pharmaceutical Company Limited
USD 278 million deal signed to secure 18 small molecule pharmaceutical product brand patents, trademarks, permits and sales rights in 9 Asia Pacific countries including South Korea
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy
Exelixis Announces Partner Takeda Receives Approval in Japan for CABOMETYX® (cabozantinib) for the Treatment of Unresectable Hepatocellular Carcinoma That Has Progressed After Prior Systemic Therapy — Approval based on results of two clinical trials in patients with advanced hepatocellular carcinoma who had received prior systemic therapy — ALAMEDA, Calif.--( BUSINESS WIRE )-- Exelixis, Inc. (NASDAQ: EXEL) today announced that Takeda Pharmaceuti
Egle Therapeutics SAS, an emerging biotechnology company focused on developing first-in class immunotherapies targeting immune suppressor regulatory T-cells for oncology and autoimmune diseases, announces that it has achieved the first milestone in its strategic research alliance with Takeda Pharmaceutical Company Limited.
Final Results from the Phase 3 HELP Study™ Open-Label Extension Support TAKHZYRO® (lanadelumab-flyo) Injection as a Long-term Preventive Treatment Option in Patients with Hereditary Angioedema
Study Results Showed Long-term Findings Consistent with the Known Safety Profile of TAKHZYRO with Reductions in the Rate of HAE Attacks and Attack-free Periods
Zhongchao Inc. announced that the Company and Takeda Pharmaceutical Company Limited agreed to expand their current scope of cooperation which now covers five of Takeda's subsidiaries in China including the new addition of Baishen Biotechnology Co., Ltd.
OrigiMed and Takeda Announced Partnership to Accelerate R&D and Commercialization of Innovative Medicines
The collaboration will develop an innovative genomic-based clinical treatment platform The goal of the collaboration is to accelerate the R&D and commercialization of innovative medicines
Takeda to Highlight Research Commitment in Bleeding Disorders and Personalized Care at American Society of Hematology (ASH) Virtual Annual Meeting
Takeda Pharmaceutical Company Limited ( TSE: 4502/NYSE:TAK ) today announced it will present nine company-sponsored abstracts at the 62 nd American Society of Hematology (ASH) Annual Meeting, being held virtually for the first time December 5-8, 2020. These data span Takeda’s extensive hematology port
Takeda Oncology Demonstrates Leadership in Hematologic Cancers at 62nd American Society of Hematology (ASH) Annual Meeting
OSAKA, Japan--( BUSINESS WIRE )-- Takeda Pharmaceutical Company Limited ( TSE:4502/NYSE:TAK ) (“Takeda”) today announced that it will present 22 company-sponsored abstracts at the 62nd American Society of Hematology (ASH) Annual Meeting,